

1       **Title: Prognostic and Diagnostic Utility of Heart Rate Variability to Predict and**  
2       **Understand Change in Cancer and Chemotherapy Related Fatigue, Pain, and**  
3       **Neuropathic Symptoms: A Systematic Review**

4

5       **Short Title: Utility of Heart Rate Variability to Predict Cancer Related Symptoms**

6

7       **Authors:**

8       Jessica Bolanos<sup>1</sup>, Layal Hneiny<sup>2</sup>, Juan Gonzalez<sup>1</sup>, Max O'Malley<sup>1</sup>, Marlon L Wong<sup>1\*</sup>

9

10       <sup>1</sup>APReCIAT Laboratory, Department of Physical Therapy, Miller School of Medicine,  
11       University of Miami, Miami, Florida, United States of America

12       <sup>2</sup>Louis Calder Memorial Library, Miller School of Medicine, University of Miami, Miami,  
13       Florida, United States of America

14

15

16       \*Corresponding author

17       E-mail: [mwong2@miami.edu](mailto:mwong2@miami.edu)

18

19

20

21

22

## 23 **Abstract**

24 Advances in early cancer detection and treatment have significantly improved  
25 survival rates, resulting in over 18.1 million cancer survivors in the United States. Many  
26 of these survivors experience chronic pain, fatigue, and neuropathic symptoms related  
27 to cancer or its treatments. Emerging evidence suggests that autonomic nervous  
28 system dysfunction plays a crucial role in these symptoms. Heart rate variability (HRV),  
29 a measure of autonomic function, has shown potential in predicting the onset of somatic  
30 symptoms in cancer patients. This systematic review aimed to assess the association of  
31 HRV with pain, fatigue, and neuropathy in cancer patients and survivors.

32 A comprehensive search was conducted across multiple databases, yielding 19  
33 studies that met inclusion criteria. These studies varied in cancer types, stages, and  
34 HRV measurement methods. Most studies focused on breast cancer and reported a  
35 predominant female population. Fatigue was the most studied symptom, followed by  
36 pain. HRV measures included both time and frequency domain variables, with  
37 significant variability in measurement duration and control for confounding factors.

38 Findings suggest that decreased HRV is associated with increased fatigue and  
39 pain, providing potential support for a bidirectional relationship between autonomic  
40 dysfunction and these symptoms. However, the heterogeneity in HRV measurement  
41 methods and the high risk of bias in many studies highlight the need for standardized  
42 HRV protocols in cancer research. Further large-scale studies with low risk of bias are  
43 necessary to validate HRV as a reliable tool for phenotyping and managing cancer-  
44 related symptoms.

## 45 Introduction

46 Advances in early detection and treatment has significantly improved 5-year  
47 cancer-specific survival rates (1). As a result, there is currently over 18.1 million cancer  
48 survivors in the United States (1), many of whom suffer from chronic pain (2), fatigue  
49 (3), or neuropathic symptoms (i.e., paresthesia and dysesthesia) associated with cancer  
50 or cancer treatments (4, 5). There is growing evidence that dysfunction of the  
51 autonomic nervous system plays a key role in the development and maintenance of  
52 these comorbid symptoms (6-8). The autonomic nervous system is an important  
53 regulator of stress responses, and it exhibits functional changes in chemotherapy  
54 induced peripheral neuropathy (CIPN) and in other chronic pain conditions (8, 9). The  
55 vagus nerve is the primary nerve of the parasympathetic system, and research indicates  
56 that the vagus nerve modulates pain through 3 pathways: 1) by maintaining autonomic  
57 and hypothalamic-pituitary-adrenal axis balance thereby reducing allostatic load (10), 2)  
58 via the cholinergic anti-inflammatory pathway in which action potentials in the vagus  
59 nerve inhibit production of TNF and other inflammatory cytokines (11), and 3) by  
60 modulating the function of brain networks involving the cingulate cortex and insula  
61 which are involved in pain processing (12). Dysfunction of these pathways may also  
62 contribute to cancer related fatigue and neuropathy (8, 9, 13).

63 Measures of heart rate variability (HRV) are commonly used as surrogate  
64 measures of autonomic function, and emerging evidence suggests that changes in HRV  
65 may predict the onset of somatic symptoms in cancer patients. In fact, a recent study  
66 found that changes in HRV preceded the onset of CIPN symptoms in people receiving  
67 oxaliplatin for gastrointestinal cancer (8), and another study found that changes in HRV

68 were correlated to sensory disturbance in people with CIPN (9). Decreased HRV has  
69 also been observed in other chronic pain populations, and it has been proposed that  
70 there is a bidirectional relationship between chronic pain and autonomic dysfunction  
71 (14). Therefore, HRV is a promising measurement tool for improving the phenotyping  
72 and measurement of cancer related somatic symptoms, and it is potentially a useful  
73 treatment target.

74 The purpose of this study was to assess the association of HRV with comorbid  
75 symptoms (i.e., pain, fatigue, and neuropathy) in cancer patients and survivors. However,  
76 the use and interpretation of HRV lacks standardization in research. Thus, this review  
77 also describes the methods used for HRV measurement in cancer research and  
78 discusses how these methods may influence findings.

## 79 **Materials and Methods**

80 A systematic review was conducted following the Methodological Expectations of  
81 Cochrane Intervention Reviews Manual (15), and the results were then reported  
82 according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses  
83 (PRISMA) (16). The review methods were established before developing the review,  
84 and the study protocol was registered at the International Prospective Register of  
85 Systematic Reviews under CRD42023418747.

## 86 **Search Strategy**

87 The study inclusion criteria consisted of 1) studies including cancer patients or  
88 survivors, and 2) longitudinal cohort studies and randomized control trials (RCTs) that

89 include at least 1 HRV measure timepoint and must include an objective measure of  
90 change for at least 1 of the symptoms listed (pain, fatigue, and/or neuropathy) or 3)  
91 cross-sectional studies that compare HRV between groups of cancer survivors with and  
92 without one of the symptoms of interest and allow for calculation of effect sizes. A  
93 search strategy was built by the clinical research librarian (LH) from Louis Calder  
94 Memorial Library together with the Primary Investigator (MW). The medical librarian  
95 (DG) reviewed it and gave an input using the Peer Review for Electronic Search  
96 Strategies tool (17).

97         Firstly, the search strategy was developed in the database Ovid using both the  
98 Medical Subject Headings for the concepts of Heart Rate Variability, Pain and Fatigue,  
99 and cancer and chemotherapy and their alternate keywords. In addition to Ovid  
100 MEDLINE(R) ALL, the following databases were searched: Cochrane Central Register  
101 of Controlled Trials (CENTRAL) (Cochrane Library, Wiley), Embase (Elsevier,  
102 Embase.com), Cumulative Index to Nursing and Allied Health Literature (CINAHL) Plus  
103 (Ebsco), the Web of Science platform (Clarivate: Science Citation Index Expanded,  
104 Social Sciences Citation Index, Arts & Humanities Citation Index, Conference  
105 Proceedings Citation Index-Science, Conference Proceedings Citation Index-Social  
106 Science & Humanities, Emerging Sources Citation Index), Scopus (Elsevier),  
107 PsycINFO, ProQuest Databases (ABI/INFORM Collection, Academic Video Online, AFI  
108 Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black  
109 Studies Center, Business Market Research Collection, Coronavirus Research  
110 Database, Digital National Security Archive, Dissertations & Theses @ University of  
111 Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch,

112 Global Newsstream, Healthcare Administration Database, Music Periodicals Database,  
113 ProQuest Civil War Era, ProQuest Dissertations & Theses Global, ProQuest Historical  
114 Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York  
115 Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest  
116 Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The  
117 Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with  
118 Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech  
119 Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide  
120 Political Science Abstracts) limited to Dissertations & Theses, and APA PsycInfo  
121 (Ebsco).

122 The Medline search strategy was adapted for the other databases each  
123 according to its syntax taking into consideration the use of different controlled  
124 vocabulary such as: Emtree terms for Embase, Medical Subject Headings for  
125 Cochrane Library, and CINAHL Subject Headings for CINAHL plus, in addition to  
126 revising the truncation, adjacency, and search fields. No application for language, date,  
127 or other limitations was applied. All databases were searched on 8,9, and 10 November  
128 2023. The full search strategy is available in Appendix 1.

## 129 **Study selection, data extraction, and data management**

130 The results that were yielded from the databases were exported into Covidence  
131 Web-based software (18) directly or into EndNote 20 (19) then imported to Covidence.  
132 In Covidence, the duplicates of overlapping results were removed, then the remaining  
133 results were first screened for title-abstract, then screened for full-text (18). Each step

134 was conducted by independently by two reviewers (JB and JG), and conflicts were  
135 resolved by consensus with the primary investigator (MW).

136 An Excel spreadsheet was developed and piloted for data extraction. Then, two  
137 independent reviewers (JB and MO) extracted data from the full-text manuscripts.  
138 Missing data was requested from the study authors via email. Seven authors were  
139 contacted in November 2024 via email requesting clarification of measures or raw data  
140 sets for symptom of interest and heart rate variability measures. Two authors responded  
141 with clarifications, two contacts were listed as undeliverable, and three authors did not  
142 respond.

## 143 **Risk of bias assessment and synthesis of findings**

144 Our intention was to include all longitudinal studies with repeated measures of  
145 HRV and symptoms, which would likely encompass a variety of study designs. Thus,  
146 the Mixed Methods Appraisal Tool (MMAT) was chosen for risk of bias assessment due  
147 to its applicability to a wide range of study types (20). Each study was assessed by two  
148 independent reviewers (JG and MO) for risk of bias, and disagreements between  
149 reviewers were resolved by deliberation until a consensus is reached (Appendix 2).

150 The body of evidence was assessed based on the Cochrane GRADE  
151 classification (high, moderate, low and very low) (21), and an Excel spreadsheet was  
152 used to record the data. Four investigators (JB, JG, MO, and MW) deliberated until  
153 consensus was achieved for Cochrane GRADE classification.

154

155

## 156 **Results**

### 157 **Study Characteristics**

158           A total of 6677 titles and abstracts were screened by two reviewers. Fifty-nine full  
159 text articles were assessed with 19 articles ultimately selected for inclusion (**Figure 1**).  
160 Publication dates ranged from 2009-2023, and the studies covered a wide range of  
161 cancer types (**Table 1**). Nine of the 19 studies focused solely on people with breast  
162 cancer (22-30). Of the 19 studies, nine (26, 28, 30-36) did not report staging  
163 information, however most that reported staging ranged from stage 0 to terminal with  
164 most participants in stage I.

165

166

167

168

169

170

171

172

173

174

175

176

177

178



179 **Table 1.** Study Characteristics

<b>First author (year)</b>	<b>Country</b>	<b>Aim of study</b>	<b>Design</b>	<b>Participants recruited</b>	<b>Heart rate variability measurement details</b>	<b>Key relevant findings</b>
Lee (2018)	Taiwan	To assess the effects of 12 weeks of Qigong exercise or stress management training on fatigue, fear of recurrence, quality of life, and heart rate variability in people who completed cancer treatment at least 1 month prior.	Randomized control trial	99 cancer survivors	5-minute recording seated or lying prone; PPG device; time domain as primary	After 12 weeks of both Qigong and stress management training, fatigue was reduced and increases in SDNN, TP and HF were observed.
Burch (2020)	USA	To assess if heart rate variability biofeedback treatment among cancer survivors can increase HRV coherence and reduce symptoms of pain, stress, fatigue, depression, distress, PTSD, and insomnia relative to control patients in 6 weeks.	Pilot randomized control trial	38 cancer survivors	15-minute recording, no positioning information mentioned; ECG device; HRV coherence ratio reported as primary	Relative to controls, the intervention group experienced trends toward improvements in stress, distress, fatigue, PTSD, and depression. HRV coherence ratio increased following biofeedback training in the intervention group while no change or decrease in coherence ratio occurred with control group.
Tsai (2021)	Taiwan	To assess what factors may influence the outcome of cancer related fatigue among female breast cancer patients undergoing chemotherapy	Cohort study	109 patients undergoing cancer treatment	15-minute recording, no positioning information given; ECG device; frequency domain as primary	Anxiety, depression, and symptom distress contributed to cancer related fatigue with symptom distress, anxiety and sleep deprivation consistently high amongst those receiving chemotherapy. No predictive

						relationship was found between LF/HF ratio and fatigue levels.
Cheng (2019)	Taiwan	To assess if 12 weeks of mindfulness or Qigong training change outcomes for fatigue and HRV in cancer survivors	Randomized control trial	66 cancer survivors	5-minute recording; no positioning information given; PPG device; time domain as primary	Reduced cancer-related fatigue was present in both the mindfulness group and the Qigong group. SDNN and TP values also increased from baseline.
Riesenberg (2009)	Germany	To assess if intensive supervised aerobic exercise is efficacious in improving HRV, quality of life, and functional status for patients with lung cancer over a 28-day period in inpatient rehab?	Cohort study	45 patients undergoing cancer treatment	12-minute recording laying down; PPG device; time domain as primary	Exercise capacity and functional status (quality of life, fatigue) improved during rehabilitation. RMSSD increased post intervention.
Chuang (2010)	Taiwan	To assess if music therapy is effective in lowering anxiety, improving mood, and improving HRV when applied for a 2-hour session one time intervention in cancer survivors	Quasi-experimental	23 cancer survivors	5-minute recording, no positioning information given; ECG device; frequency domain as primary	Fatigue levels were lower after music therapy. Increase in HF power and decrease in LF/HF ratio and LF power were observed post intervention.
Fernandez-Lao (2011)	Spain	To investigate the immediate effects of myofascial release on HRV and mood state and to assess the attitude towards massage in breast cancer survivors suffering cancer-related fatigue	Crossover randomized control trial	20 cancer survivors	5min ECG, no positioning information given; ECG device; time domain as primary	Massage leads to an immediate increase in SDNN, RMSSD and HF and an improvement in mood. The impact of massage on cancer-related fatigue is modulated by the attitude of the patient towards massage, however no interaction was

						reported between belief and SDNN, RMSSD or HF values.
Chen (2019)	Taiwan	To assess the effect of a single music therapy intervention on multiple mood categories and HRV for women actively being treated for breast cancer.	Randomized control trial	100 patients undergoing cancer treatment	5-minute recording, no positioning information given; ECG device; frequency domain as primary	Women who completed single session music intervention reduced symptoms post intervention compared to control group. Higher LF/HF ratio reported at baseline, but no post intervention data was given.
Aoki (2023)	Japan	To assess if HRV would be useful in evaluating fatigue and quality of life of women with breast cancer undergoing radiotherapy.	Cohort study	75 patients undergoing cancer treatment	2-minute recording, sitting; PPG device; frequency domain as primary	Cognitive and physical fatigue were highest at baseline and decreased by midpoint of treatment. Similarly, a decrease in LF/HF ratio was seen by midpoint of treatment.
Masel (2016)	Austria	To assess if HRV a valid representation for subjective pain for patients in palliative care with cancer break through pain.	Pilot study	10 patients undergoing cancer treatment	24-hour recording, no positioning data given; ECG device; frequency domain as primary	Pain reduction was seen post opioid administration. Log LF/HF ratio decreased in patients with >2 point reduction on the NRS.
Lee (2022)	Taiwan	To assess if there is a difference in HRV measures and quality of life measures when given either Qigong, mindfulness intervention or no intervention in cancer survivors at least 1 month out of treatment.	Quasi-experimental	125 cancer survivors	5-minute recording, sitting; PPG device; time domain as primary	Both Qigong and mindfulness interventions had short-term effects in improving overall physical and mental health, and quality of life. Increase in SDNN and total power were noted in the short term, but decreased LF was reported in the long term.

Uchida (2017)	Japan	To assess if HRV is predictive of PACU emergent pain within a 12h hour window in post operative breast cancer surgery patients.	Retrospective study	20 patients undergoing cancer treatment	No positioning or recording time information given; PPG device; frequency domain as primary	There was no significant difference in pain intensity between the two groups immediately after admission to PACU. Patients in the intervention group required no analgesic agents for at least 12 hours after surgery. Increased HF and decreased LF/HF ratio values were associated with adequate pain intervention.
Fagundes (2011)	USA	To assess if fatigue level is related to HRV or epinephrine at baseline and during/after a social stressor in breast cancer survivors.	Cohort study	109 cancer survivors	Continuous recording, sitting; PPG device; time domain as primary	Higher fatigue was associated with decreased RMSSD values pre and post stressor.
Niederer (2013)	Germany	To assess if exercise over a 16-week period improves HRV measures and cancer related fatigue in both cancer survivors and patients undergoing cancer treatment.	Quasi-experimental	45 cancer survivors and those undergoing treatment	5-minute recordings, supine; PPG device; frequency domain as primary	Exercise programming improves quality of life and increases total power values. An increase in HF and decrease in LF was also observed post intervention.
Yesil (2018)	Turkey	To assess whether neuropathic pain is associated with changes in cardiac sympathovagal activity in patients with breast cancer.	Cohort study	70 patients undergoing cancer treatment	24-hour recording, no positioning information given; ECG device; time domain as primary	SDNN was lower and LF/HF ratio was higher in patients with neuropathic pain than in those without.
Fournié (2021)	France	To evaluate the feasibility of a 12-week program combining heart rate variability biofeedback and physical	Cohort study	20 patients undergoing cancer treatment	5-minute recording, seated with knees at 90°, feet flat on the floor, hands on	No changes in fatigue outcome measures noted despite a trend towards decreasing general/physical fatigue. SDNN and RMSSD did not change

		exercise in hematologic patients.			thighs, palms facing upward, and eyes closed; PPG device; time domain as primary	over time, but increased LF and HRV coherence ratio were noted.
Murofushi (2023)	Japan	To assess if HRV can provide an objective measure for bone metastasis pain during a period of radiotherapy.	Pilot study	11 patients undergoing cancer treatment	24-hour recording, no positioning information given; PPG device; frequency domain as primary	For all samples, the NRS score showed no significant relationship with mean LF/HF ratio and HF. In patients with an NRS $\geq 4$ , the NRS score was significantly associated with LF/HF ratio but not HF.
Guimond (2018)	Canada	To assess if measures of emotional regulation are associated with measures of psychological symptoms in patients with breast cancer receiving radiotherapy.	Cross-sectional	81 patients undergoing cancer treatment	5-minute recording, no positioning information given; PPG device; time domain as primary	Low emotional regulation was marginally associated with increased depression and fatigue between timepoints. HF was not associated with symptom change.
Uchida (2017)	Japan	To assess if low dose Remifentanil effects post operative pain and HRV in breast cancer surgery patients.	Retrospective study	20 patients undergoing cancer treatment	No positioning or recording time information given; PPG device; frequency domain as primary	After Remifentanil administration, the value of the NRS decreased. There were no significant differences in HF and LF/HF ratio was found between groups.

180

181 *PPG= photoplethysmogram; SDNN= standard deviation of the normal-to-normal interval; TP= total power; HF= high*  
 182 *frequency power; PTSD= post-traumatic stress syndrome; HRV= heart rate variability; ECG=electrocardiogram; LF/HF*  
 183 *ratio= low frequency/high frequency ratio; RMSSD = square root of mean squared differences of successive normal-to-*  
 184 *normal intervals; NRS= numeric rating scale; LF= low frequency; PACU= post anesthesia care unit*

185 A majority of the participants across studies were middle aged (ranging from 48-  
186 65 years). All but 3 of the studies (34-36) reported a predominant female population,  
187 with 10 having an all-female sample (22-31). One study did not provide gender  
188 information (37). Studies took place in Taiwan (N= 6)(22, 24, 31, 33, 38, 39), Japan (N =  
189 4)(25, 26, 30, 36), United States of America (USA) (N = 2)(27, 40), Germany (N = 2)(34,  
190 37), Canada (N = 1)(29), France (N = 1)(35), Turkey (N = 1)(28), Spain (N = 1)(23), and  
191 Austria (N = 1)(32). Only 2 studies provided detailed data on race or ethnicity, and these  
192 studies took place in the USA (27, 40).

193 Fatigue was the most common symptom discussed (N = 14)(22-25, 27, 29, 31,  
194 33-35, 37-39), followed by pain (N = 5)(26, 30, 32, 36). Although 1 study assessed  
195 neuropathic pain,(28) no studies were found on non-painful neuropathic symptoms, and  
196 only 1 study assessed multiple symptoms (pain and fatigue) (40). Four of the included  
197 studies were focused on the psychological effects of cancer (mood, anxiety, depression)  
198 as a primary measure, with fatigue as a secondary measure of interest (22, 23, 31, 39).

### 199 **Heart rate variability measures**

200 All 19 studies utilized electrocardiogram (ECG) (N=6) or photoplethysmography  
201 (PPG) (N=13) equipment in the form of wrist watches, handheld or chest strap tools for  
202 HRV measurement. Ten of 19 studies conducted HRV measurements for 5 minutes or  
203 less.(23-25, 29, 31, 33-35, 38, 39) 3 of 19 reported between 12 and 15-minute  
204 recording times.(22, 37, 40) Furthermore, 4 of 19 reported continuous measurement for  
205 a maximum of 24 hours.(27, 28, 32, 36) Two studies did not report on the duration of  
206 the recording.(26, 30) Studies varied in participant positioning during HRV recording  
207 and in level of control for confounding factors (i.e. caffeine, physical activity), with 7 of

208 19 studies failing to include this information in the manuscript (22, 26, 30, 32, 33, 36,  
209 39).

## 210 **Heart rate variability and fatigue**

211 Fatigue was a primary outcome for 9 studies (24, 25, 27, 29, 33-35, 37, 38).

212 Participants included cancer stages from stage I-IV, and sample sizes ranged from 17-

213 125. Measures of fatigue were heterogeneous amongst the studies, and included the

214 cancer fatigue scale (N= 3)(25, 33, 38), multidimensional fatigue inventory (MFI-20)

215 (N=2)(35, 37), multidimensional fatigue symptom inventory (MFSI-SF) (N= 2)(24, 27),

216 fatigue symptom inventory (N=1)(29) and the EORTC Core Quality of Life questionnaire

217 (EORTC-QLQ C30) (N=1)(34).

218 Five of the 9 studies reported time domain measures. Standard deviation of

219 normal-to-normal RR intervals (SDNN) was utilized for three studies (33, 35, 38). Root

220 mean square of successive differences (RMSSD) was reported as a primary time

221 domain variable in 2 studies (27, 37). Of these 5 studies, only one did not report

222 secondary frequency domain variables (LF, HF, LF/HF ratio) (37). Furthermore, four of

223 9 studies only reported frequency domain variables (24, 25, 29, 34).

224 All 9 studies reported longitudinal HRV measures at distinct time points (pre

225 intervention, post intervention, follow up). Time periods between baseline and follow up

226 measures were variable, with final follow up outcome assessment ranging between 12-

227 28 weeks after initial intervention. HRV devices were worn for 5-15 minutes throughout

228 the data collection process for all 9 studies, and 8 of the fatigue related studies reported

229 controlling for confounding factors of HRV including quiet sitting, decreasing caffeine

230 (24, 25, 27, 29, 34, 37, 38), and specific instructions like “relax and breathe  
231 normally”(35).

232 Across 4 of the studies (27, 33, 37, 38), a decrease in fatigue scores was  
233 associated with increased time domain HRV measures (SDNN, RMSSD). Only one  
234 study found no change in time domain measures amongst groups (35). The  
235 relationships between fatigue scores and frequency domain measures (LF/HF ratio, HF,  
236 LF, TP) were mixed with two studies reporting no change in the trials (29, 35), one study  
237 reporting decreased LF/HF ratio and fatigue at midpoint of treatment (25), and 3 studies  
238 reporting increased total power with decreased fatigue (33, 34, 38).

### 239 **Studies using heart rate variability with fatigue as secondary measures**

240 Four studies included fatigue measures as a secondary focus, with a primary  
241 focus on emotional stressors like anxiety, depression or fear of cancer recurrence (22,  
242 23, 31, 39). Like the studies with fatigue as a primary outcome, sample sizes varied  
243 from 20-100 participants (23, 31, 39). All 4 studies utilized ECG as a primary source of  
244 HRV measurement, with recordings lasting 5-15 minutes, with 2 reporting time domain  
245 variables as primary HRV outcomes (SDNN, RMSSD)(23, 39), and all four studies  
246 reported frequency domain measures (LF/HF ratio, TP, HF, LF). Three of the studies  
247 found that an improvement in HRV variables (increased SDNN, RMSSD, HF and  
248 decreased LF/HF ratio) occurred with decreased fatigue (23, 31, 39). Only one study  
249 found no predictive relationship between HRV and cancer related fatigue, and though  
250 this study had the largest sample size, it was also the only study involving participants  
251 currently undergoing cancer treatment (22).



252           Across these 13 studies, a decrease in fatigue scores typically occurred with an  
253 increase in time domain HRV measures, with only 1 of 7 studies that reported on time  
254 domain measures not finding this relationship. There was less consistency across  
255 fatigue related studies that used frequency domain HRV measures, although most also  
256 found a relationship. The GRADE for the evidence on HRV as a physiological marker for  
257 fatigue is **low** due to risk of bias (incomplete outcome data in 4 studies and lack of  
258 accounting for confounders in 2 studies).

## 259 **Heart rate variability and pain**

260           Of the 4 studies with pain as the primary symptom under investigation,  
261 participants ranged in cancer stage of treatment from post operative to palliative care,  
262 and all of the studies had small sample sizes ( $n \leq 20$ ). All 4 studies utilized the 0-10  
263 numeric rating scale (NRS) for pain intensity, and none reported any additional pain  
264 variables. Additionally, all 4 studies utilized frequency domain HRV measures including  
265 high frequency (HF), low frequency (LF), total power (TP), and LF/HF ratio; and only  
266 one study reported a time domain variable (pNN50). Only 2 of the studies reported  
267 recording time frame (24 hours for both) (32, 36). HRV measurement with a PPG based  
268 monitoring system was closely tied to time periods of medication administration for pain  
269 management in 3 of 4 studies (26, 30, 32). Importantly, none of the four studies reported  
270 controlling for confounding factors pertaining to HRV measurement (e.g., time of day,  
271 phase of menstrual cycle, dietary and exercise considerations).

272           Three studies reported on acute pain changes (i.e., post operative and  
273 breakthrough pain)(26, 30, 32) and one on chronic pain associated with bony  
274 metastasis (36). Those studies on acute pain reported significant differences in

275 frequency domain variables, mainly LF/HF ratio, with improving NRS scores (26, 30,  
276 32). Two studies reported on the role of pain free post operative period in regulating  
277 HRV (LF/HF ratio and HF) (26, 30). With breakthrough pain specifically, an NRS  
278 reduction of greater than 2 points equated to a decrease in LF/HF ratio and improving  
279 function (32). With radiotherapy, higher NRS scores of greater than or equal to 4 were  
280 associated with LF/HF ratio changes with no significant association found with NRS  
281 scores below 4 (36).

282 Collectively, these studies suggest that moderate changes in pain intensity (NRS  
283 change of 2-4) may be associated with changes in HRV. However, the GRADE for this  
284 evidence is **very low** due to high risk of bias (incomplete reporting of data and lack of  
285 accounting for confounders) and imprecision (small sample sizes).

## 286 **Heart rate variability and neuropathy**

287 Only one study mentioned neuropathy as a symptom of interest in conjunction  
288 with pain measures (28). Categorized as neuropathic pain, the study focused on breast  
289 cancer patients, and no cancer stage information was given. Unlike the other studies on  
290 pain, this study utilized the Leeds Assessment of Neuropathic Symptoms and Signs  
291 (LANSS) scale to differentiate between neuropathic and nociceptive pain descriptors,  
292 not intensity (28). ECG was utilized to measure HRV, with SDNN being the HRV  
293 variable of interest. Other time domain variables (SD of the mean of the RR intervals  
294 (SDAAN), SD of the NN interval (SDDN index) and frequency domain variables (total  
295 power (TP), LF/HF ratio) were also collected. Time domain variable values were found  
296 to be lower and frequency domain variable values were found to be higher in those with  
297 neuropathic pain (28). The GRADE for the evidence on HRV as a physiological marker

298 for neuropathy is **very low** due to high risk of bias (lack of accounting for confounders)  
299 and imprecision (only 1 study).

## 300 **Discussion**

301 HRV is a complex measure involving the fluctuation in the time intervals between  
302 heartbeats. These changes can influence regulatory outputs like blood pressure, heart  
303 and vascular tone, which influences adaptation to both physical and psychological  
304 stressors (41). This study aimed to assess the relationship of HRV to comorbid  
305 symptoms (i.e., pain, fatigue, and neuropathy) in cancer patients and survivors.  
306 Nineteen studies were identified that utilized HRV and assessed pain or fatigue.  
307 However, they varied in their purpose and application of HRV with some using HRV to  
308 determine the impact of symptoms on autonomic function and others using HRV as a  
309 measure of systemic response to a targeted intervention.

### 310 **HRV confounders**

311 HRV measurements can be influenced by a variety of variables, including age,  
312 sex, and breathing rate (41). Numerous lifestyle factors including stress level, smoking,  
313 fitness level, caffeine intake and pharmacology, can also have an influence on HRV  
314 metrics (42). Thus, control and identification of these confounding factors is of utmost  
315 importance to decrease error in HRV interpretation. In our sample of studies, 7 of 19  
316 included a description of controlling for potential confounders of HRV.

317 Additionally, sampling time can have an influence on accuracy of HRV metrics.  
318 The “gold standard” for clinical assessment is a 24 hour recording, as these recordings

319 are shown to have greater predictive power (41). Short term measurements, defined as  
320 5 minute measurements, or ultra short term measurements (<5 minutes) have been  
321 found to correlate poorly with the 24-hour indices (41). Of the 19 articles reviewed, 10  
322 reported short term or ultra short-term measurements, and only 4 utilized 24-hour  
323 measurements. This may be a contributing factor to the heterogeneity in findings.

324 Further contributing to the heterogeneity, HRV can be divided into time,  
325 frequency, and spectral domain measures. Notably, only time and frequency domain  
326 measures were reported, as none of the 19 studies assessed spectral domain  
327 measures. Time domain HRV indices (i.e. SDNN, RMSSD, pNN50, HRmax-HRmin)  
328 quantify the amount of variability observed during a recording time frame (<1 minute to  
329 >24 hours) (41). The SDNN has been referred to as the “gold standard” HRV variable  
330 for medical stratification of cardiovascular risk when recorded over a 24-hour period (41,  
331 43). In contrast, frequency domain HRV indices estimate the relative or absolute power  
332 over four frequency bands ultra-low frequency (ULF), very-low frequency (VLF), low-  
333 frequency (LF) and high-frequency (HF) (41). The ratio of LF to HF (LF/HF ratio) was  
334 originally interpreted as an estimate of sympathetic to parasympathetic balance, with  
335 low LF/HF ratio symbolizing parasympathetic dominance and high LF/HF ratio  
336 translating to sympathetic dominance (41). This interpretation contributes to the  
337 popularity of frequency domain variables being reported over time domain. However,  
338 the accuracy of this interpretation has been called into question due to the variable  
339 nature of sympathetic nervous system control. Moreover, LF/HF ratio, particularly short  
340 term measurements of LF/HF ratio, have been found to vary widely based on testing  
341 conditions (41). Kuss et al. (44) found that frequency domain variables showed up to a

342 10 fold increase in variation when compared to SDNN. Of the 19 studies examined, only  
343 9 reported a time domain measure (SDNN or RMSSD), and 17 studies reported  
344 frequency domain measures, most commonly LF/HF ratio. The higher utilization of  
345 frequency domain variables over time domain variables goes against existing  
346 recommendations for HRV research, and it highlights the need for consensus guidelines  
347 on HRV research in cancer populations.

## 348 **Differences in Outcome Measures**

349 The specific outcome measure chosen may also influence the observed  
350 relationships between HRV and pain or fatigue. The four studies on pain were noted to  
351 all utilize the same outcome measure (NRS), focusing on pain intensity with  
352 pharmacological interventions. However, pain is known to be multidimensional (45), and  
353 the pain NRS is a unidimensional measure. It is possible that changes in HRV are  
354 associated with aspects of pain other than intensity (e.g., pain interference on mood or  
355 sleep). In contrast, the studies that focused on fatigue utilized multidimensional  
356 measures of fatigue. Specifically, the Cancer Fatigue Scale (CFS), Fatigue Symptom  
357 Inventory (FSI) and Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-  
358 SF) were all validated utilizing patients with a history of cancer and all measure  
359 physical, cognitive and emotional fatigue (46-48). However, outcome scores for these  
360 fatigue scales were usually reported as a total score change, with only one study  
361 reporting subscale changes (35). It is plausible that HRV is more closely associated with  
362 one aspect of fatigue than another (e.g., physical fatigue may be strongly correlated to  
363 HRV but emotional fatigue is not). Given the multidimensional nature of pain and

364 fatigue, future studies on HRV should assess and report on multiple dimensions for the  
365 symptoms of interest.

## 366 **Limitations**

367 Only articles in English were included, which is an important limitation of the  
368 review process used in this study. Additionally, our search yielded only one study on  
369 HRV and neuropathy, and this study focused on neuropathic pain. The lack of  
370 longitudinal studies on HRV and neuropathy may be influenced by the lack of  
371 consensus regarding the diagnostic criteria for chemotherapy induced peripheral  
372 neuropathy (CIPN)(8). Another potential reason for this may be that CIPN is only found  
373 with neurotoxic chemotherapies such as paclitaxel, cisplatin, and oxaliplatin which may  
374 not have been prescribed in a large portion of the included abstracts for review (49).  
375 Due to the heterogeneity of the HRV measurements and the relatively high risk of bias  
376 across studies, we did not conduct a meta-analysis as planned. Additionally, only 2 of  
377 19 studies reported on race/ethnicity in their given populations, and 10 of 19 studies  
378 took place in Asia (Taiwan, Japan), which may limit the generalizability of these findings.

## 379 **Conclusion**

380 HRV is growing in use as a physiological outcome measure, and the findings of  
381 this study suggest that it may be a useful tool to determine physiological load  
382 associated with fatigue and pain in cancer patients and survivors. Fatigue and pain are  
383 common comorbidities associated with antineoplastic treatment and while their  
384 physiological impact can be seen with HRV changes, the lack of consensus with HRV

385 measurement can make its interpretation difficult. Large studies with low risk of bias are  
386 needed as the field continues to work toward better standardization of HRV protocols.

## 387 **Acknowledgements**

388 For peer reviewing the Medline (OVID) database search strategy, the authors  
389 would like to acknowledge the Research Services and Liaison Librarian David S.  
390 Gerstle, Ph.D., MS-ILS from the University of Toronto Mississauga. The authors would  
391 also like to acknowledge John Reynolds and Thilani Samarakoon for their input on  
392 methodology.

## 393 **References**

- 394 1. Tonorezos E, Devasia T, Mariotto AB, Mollica MA, Gallicchio L, Green P, et al.  
395 Prevalence of cancer survivors in the United States. *J Natl Cancer Inst.* 2024;116(11):1784-  
396 90.
- 397 2. Arthur J, Tanco K, Park M, Haider A, Maligi C, Dalal S, et al. Personalized Pain Goal as  
398 an Outcome Measure in Routine Cancer Pain Assessment. *J Pain Symptom Manage.*  
399 2018;56(1):80-7.
- 400 3. Prue G, Rankin J, Allen J, Gracey J, Cramp F. Cancer-related fatigue: A critical  
401 appraisal. *Eur J Cancer.* 2006;42(7):846-63.
- 402 4. Kerckhove N, Collin A, Conde S, Chaletex C, Pezet D, Balayssac D. Long-Term  
403 Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced  
404 Peripheral Neuropathies: A Comprehensive Literature Review. *Front Pharmacol.* 2017;8:86.
- 405 5. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence,  
406 prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic  
407 review and meta-analysis. *Pain.* 2014;155(12):2461-70.
- 408 6. Stone CA, Kenny RA, Nolan B, Lawlor PG. Autonomic dysfunction in patients with  
409 advanced cancer; prevalence, clinical correlates and challenges in assessment. *BMC*  
410 *Palliat Care.* 2012;11:3.
- 411 7. Noor B, Akhavan S, Leuchter M, Yang EH, Ajjola OA. Quantitative assessment of  
412 cardiovascular autonomic impairment in cancer survivors: a single center case series.  
413 *Cardiooncology.* 2020;6:11.
- 414 8. Jang A, Seol YM. Heart Rate Variability as a Non-invasive Objective Parameter for  
415 Predicting the Occurrence of Chemotherapy-induced Peripheral Neuropathy in Patients  
416 With Gastrointestinal Cancer. *Anticancer Res.* 2021;41(5):2637-45.



- 417 9. Marstrand SD, Buch-Larsen K, Andersson M, Jensen LT, Schwarz P. Vibration  
418 Perception Threshold and Heart Rate Variability as methods to assess chemotherapy-  
419 induced neuropathy in women with breast cancer - a pilot study. *Cancer Treat Res*  
420 *Commun.* 2021;28:100426.
- 421 10. Li S, Wang Y, Gao G, Guo X, Zhang Y, Zhang Z, et al. Transcutaneous Auricular Vagus  
422 Nerve Stimulation at 20 Hz Improves Depression-Like Behaviors and Down-Regulates the  
423 Hyperactivity of HPA Axis in Chronic Unpredictable Mild Stress Model Rats. *Front Neurosci.*  
424 2020;14:680.
- 425 11. Chavan SS, Pavlov VA, Tracey KJ. Mechanisms and Therapeutic Relevance of Neuro-  
426 immune Communication. *Immunity.* 2017;46(6):927-42.
- 427 12. Mao Y, Chen C, Falahpour M, MacNiven KH, Heit G, Sharma V, et al. Effects of Sub-  
428 threshold Transcutaneous Auricular Vagus Nerve Stimulation on Cingulate Cortex and  
429 Insula Resting-state Functional Connectivity. *Front Hum Neurosci.* 2022;16:862443.
- 430 13. Garcia-Gonzalez D, Medino-Munoz J, Romero-Elias M, Garcia-Foncillas J, Ruiz-  
431 Casado A. Biological mechanisms of cancer-related fatigue in breast cancer survivors after  
432 treatment: a scoping review. *J Cancer Surviv.* 2023.
- 433 14. Arslan D, Unal Cevik I. Interactions between the painful disorders and the  
434 autonomic nervous system. *Agri.* 2022;34(3):155-65.
- 435 15. Higgins JPT LT, Chandler J, Tovey D, Churchill R. *Methodological Expectations of*  
436 *Cochrane Intervention Reviews: Cochrane; 2016.*
- 437 16. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA  
438 2020 explanation and elaboration: updated guidance and exemplars for reporting  
439 systematic reviews. *BMJ.* 2021;372:n160.
- 440 17. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer  
441 Review of Electronic Search Strategies: 2015 Guideline Statement. *J Clin Epidemiol.*  
442 2016;75:40-6.
- 443 18. Covidence systematic review software. Melbourne, Australia: Veritas Health  
444 Innovation.
- 445 19. Team TE. EndNote. EndNote 20 ed. Philadelphia, PA: Clarivate; 2013.
- 446 20. Pace R, Pluye P, Bartlett G, Macaulay AC, Salsberg J, Jagosh J, et al. Testing the  
447 reliability and efficiency of the pilot Mixed Methods Appraisal Tool (MMAT) for systematic  
448 mixed studies review. *Int J Nurs Stud.* 2012;49(1):47-53.
- 449 21. Schünemann HJ HJ, Vist GE, Glasziou P, Akl EA, Skoetz N, Guyatt GH. Chapter 14:  
450 Completing 'Summary of findings' tables and grading the certainty of the evidence. 2023.  
451 In: *Cochrane Handbook for Systematic Reviews of Interventions version 65 [Internet].*  
452 [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook): Cochrane.
- 453 22. Tsai HY, Wang CJ, Mizuno M, Muta R, Fetzer SJ, Lin MF. Predictors of cancer-related  
454 fatigue in women with breast cancer undergoing 21 days of a cyclic chemotherapy.  
455 *Worldviews on Evidence-Based Nursing.* 2022;19(3):211-8.
- 456 23. FernÁNdez-Lao C, Cantarero-Villanueva I, DÍAz-Rodríguez L, Cuesta-Vargas AI,  
457 FernÁNdez-Delas-PeÑAs C, Arroyo-Morales M. Attitudes towards massage modify effects  
458 of manual therapy in breast cancer survivors: a randomised clinical trial with crossover  
459 design. *European Journal of Cancer Care.* 2012;21(2):233-41.



- 460 24. Chen S-C, Yeh M-L, Chang H-J, Lin M-F. Music, heart rate variability, and symptom  
461 clusters: a comparative study. *Supportive Care in Cancer*. 2020;28(1):351-60.
- 462 25. Aoki M, Kuratsune H, Yamamoto S, Hirano T, Hanaeda K, Nishi Y, et al. Autonomic  
463 function measurements for evaluating fatigue and quality of life in patients with breast  
464 cancer undergoing radiation therapy: a prospective longitudinal study. *Radiation Oncology*.  
465 2023;18(1):171.
- 466 26. Uchida S, Kadoi Y, Saito S. Differences in heart rate variability may be related to the  
467 appearance of postoperative pain in patients undergoing breast cancer surgery. *JA Clinical*  
468 *Reports*. 2017;3(1):56.
- 469 27. Fagundes CP, Murray DM, Hwang BS, Gouin J-P, Thayer JF, Sollers III JJ, et al.  
470 Sympathetic and parasympathetic activity in cancer-related fatigue: more evidence for a  
471 physiological substrate in cancer survivors. *Psychoneuroendocrinology*. 2011;36(8):1137-  
472 47.
- 473 28. Yesil H, Eyigor S, Kayikcioglu M, Uslu R, Inbat M, Ozbay B. Is neuropathic pain  
474 associated with cardiac sympathovagal activity changes in patients with breast cancer?  
475 *Neurological Research*. 2018;40(4):297-302.
- 476 29. Guimond A-J, Ivers H, Savard J. Is emotion regulation associated with cancer-related  
477 psychological symptoms? *Psychology & Health*. 2019;34(1):44-63.
- 478 30. Uchida S, Kadoi Y, Saito S. Effect of Low Dose Remifentanyl on Postoperative Pain  
479 Relief and Heart Rate Variability in Post-Anaesthesia Care Unit. *Turk Anestezi Ve*  
480 *Reanimasyon Dergisi*. 2017;45(5):297-302.
- 481 31. Chuang C-Y, Han W-R, Li P-C, Young S-T. Effects of music therapy on subjective  
482 sensations and heart rate variability in treated cancer survivors: a pilot study.  
483 *Complementary therapies in medicine*. 2010;18(5):224-6.
- 484 32. Masel EK, Huber P, Engler T, Watzke HH. Heart rate variability during treatment of  
485 breakthrough pain in patients with advanced cancer: a pilot study. *Journal of pain research*.  
486 2016;9:1215-20.
- 487 33. Lee Y-H, Chang Y-P, Lee J-T, Lee D-C, Huang E-Y, Lai L-JT. Heart rate variability as an  
488 indicator of the beneficial effects of Qigong and mindfulness training on the mind–body  
489 well-being of cancer survivors. *Supportive Care in Cancer*. 2023;31(1):59.
- 490 34. Niederer D, Vogt L, Thiel C, Schmidt K, Bernhörster M, Lungwitz A, et al. Exercise  
491 Effects on HRV in Cancer Patients. *International Journal of Sports Medicine*. 2013;34(1):68-  
492 73.
- 493 35. Fournié C, Verkindt C, Dalleau G, Bouscaren N, Mohr C, Zunic P, et al. Rehabilitation  
494 program combining physical exercise and heart rate variability biofeedback in hematologic  
495 patients: a feasibility study. *Support Care Cancer*. 2022;30(3):2009-16.
- 496 36. Murofushi KN, Komazawa M, Murofushi W, Hayakawa S, Ito K, Shimizuguchi T, et al.  
497 Preliminary Study on Establishing a Heart Rate Variability-based Method for Objectively  
498 Evaluating Bone Metastasis Pain. *In Vivo*. 2023;37(2):940-7.
- 499 37. Riesenbergh H, Lübbe AS. In-patient rehabilitation of lung cancer patients—a  
500 prospective study. *Supportive Care in Cancer*. 2010;18:877-82.
- 501 38. Lee Y-H, Lai G-M, Lee D-C, Tsai Lai L-J, Chang Y-P. Promoting Physical and  
502 Psychological Rehabilitation Activities and Evaluating Potential Links Among Cancer-

503 Related Fatigue, Fear of Recurrence, Quality of Life, and Physiological Indicators in Cancer  
504 Survivors. *Integrative Cancer Therapies*. 2018;17(4):1183-94.

505 39. Cheng T-C, Lee Y-H, Mar C-L, Huang W-T, Chang Y-P. The health promoting  
506 mindfulness or Qigong educational programs for beneficial lifestyle changes of cancer  
507 survivors. *Journal of Cancer Education*. 2020;35:743-50.

508 40. Burch JB, Ginsberg J, McLain AC, Franco R, Stokes S, Susko K, et al. Symptom  
509 management among cancer survivors: Randomized pilot intervention trial of heart rate  
510 variability biofeedback. *Applied psychophysiology and biofeedback*. 2020;45:99-108.

511 41. Shaffer F, Ginsberg JP. An Overview of Heart Rate Variability Metrics and Norms.  
512 *Front Public Health*. 2017;5:258.

513 42. Sammito S, Böckelmann I, editors. Factors influencing heart rate variability.  
514 *International Cardiovascular Forum Journal*; 2016.

515 43. Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, et al. Cardio-  
516 oncology rehabilitation to manage cardiovascular outcomes in cancer patients and  
517 survivors: a scientific statement from the American Heart Association. *Circulation*.  
518 2019;139(21):e997-e1012.

519 44. Kuss O, Schumann B, Kluttig A, Greiser KH, Haerting J. Time domain parameters can  
520 be estimated with less statistical error than frequency domain parameters in the analysis  
521 of heart rate variability. *Journal of electrocardiology*. 2008;41(4):287-91.

522 45. Ahles TA, Martin JB. Cancer pain: a multidimensional perspective. *Hosp J*. 1992;8(1-  
523 2):25-48.

524 46. Okuyama T, Akechi T, Kugaya A, Okamura H, Shima Y, Maruguchi M, et al.  
525 Development and validation of the cancer fatigue scale: a brief, three-dimensional, self-  
526 rating scale for assessment of fatigue in cancer patients. *Journal of pain and symptom*  
527 *management*. 2000;19(1):5-14.

528 47. Shahid A, Wilkinson K, Marcu S, Shapiro CM. Multidimensional fatigue inventory  
529 (MFI). *STOP, THAT and one hundred other sleep Scales*: Springer; 2011. p. 241-3.

530 48. Stein KD, Jacobsen PB, Blanchard CM, Thors C. Further validation of the  
531 multidimensional fatigue symptom inventory-short form. *Journal of pain and symptom*  
532 *management*. 2004;27(1):14-23.

533 49. Jang A, Kim DU. The relationship between chemotherapy-induced peripheral  
534 neuropathy and heart rate variability. *American Society of Clinical Oncology*; 2020.

## 535 **Figure and Table Legend**

536 Figure 1. PRISMA Flow Diagram


537 Table 1. Study Characteristics

538 Appendix 1. Full Search Strategy

539 Appendix 2. Mixed Methods Appraisal Tool Results

**Figure 1. PRISMA Flow Diagram**

medRxiv preprint doi: <https://doi.org/10.1101/2025.01.08.25320191>; this version posted January 8, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



<b>First author (year)</b>	<b>Country</b>	<b>Aim of study</b>	<b>Design</b>	<b>Participants recruited</b>	<b>Heart rate variability measurement details</b>	<b>Key relevant findings</b>
Lee (2018)	Taiwan	To assess the effects of 12 weeks of Qigong exercise or stress management training on fatigue, fear of recurrence, quality of life, and heart rate variability in people who completed cancer treatment at least 1 month prior.	Randomized control trial	99 cancer survivors	5-minute recording seated or lying prone; PPG device; time domain as primary	After 12 weeks of both Qigong and stress management training, fatigue was reduced and increases in SDNN, TP and HF were observed.
Burch (2020)	USA	To assess if heart rate variability biofeedback treatment among cancer survivors can increase HRV coherence and reduce symptoms of pain, stress, fatigue, depression, distress, PTSD, and insomnia relative to control patients in 6 weeks.	Pilot randomized control trial	38 cancer survivors	15-minute recording, no positioning information mentioned; ECG device; HRV coherence ratio reported as primary	Relative to controls, the intervention group experienced trends toward improvements in stress, distress, fatigue, PTSD, and depression. HRV coherence ratio increased following biofeedback training in the intervention group while no change or decrease in coherence ratio occurred with control group.
Tsai (2021)	Taiwan	To assess what factors may influence the outcome of cancer related fatigue among female breast	Cohort study	109 patients undergoing cancer treatment	15-minute recording, no positioning information given; ECG device;	Anxiety, depression, and symptom distress contributed to cancer related fatigue with symptom distress, anxiety

		cancer patients undergoing chemotherapy			frequency domain as primary	and sleep deprivation consistently high amongst those receiving chemotherapy. No predictive relationship was found between LF/HF ratio and fatigue levels.
Cheng (2019)	Taiwan	To assess if 12 weeks of mindfulness or Qigong training change outcomes for fatigue and HRV in cancer survivors	Randomized control trial	66 cancer survivors	5-minute recording; no positioning information given; PPG device; time domain as primary	Reduced cancer-related fatigue was present in both the mindfulness group and the Qigong group. SDNN and TP values also increased from baseline.
Riesenberg (2009)	Germany	To assess if intensive supervised aerobic exercise is efficacious in improving HRV, quality of life, and functional status for patients with lung cancer over a 28-day period in inpatient rehab?	Cohort study	45 patients undergoing cancer treatment	12-minute recording laying down; PPG device; time domain as primary	Exercise capacity and functional status (quality of life, fatigue) improved during rehabilitation. RMSSD increased post intervention.
Chuang (2010)	Taiwan	To assess if music therapy is effective in lowering anxiety, improving mood, and improving HRV when applied for a 2-hour session one time intervention in cancer survivors	Quasi-experimental	23 cancer survivors	5-minute recording, no positioning information given; ECG device; frequency domain as primary	Fatigue levels were lower after music therapy. Increase in HF power and decrease in LF/HF ratio and LF power were observed post intervention.

Fernandez-Lao (2011)	Spain	To investigate the immediate effects of myofascial release on HRV and mood state and to assess the attitude towards massage in breast cancer survivors suffering cancer-related fatigue	Crossover randomized control trial	20 cancer survivors	5min ECG, no positioning information given; ECG device; time domain as primary	Massage leads to an immediate increase in SDNN, RMSSD and HF and an improvement in mood. The impact of massage on cancer-related fatigue is modulated by the attitude of the patient towards massage, however no interaction was reported between belief and SDNN, RMSSD or HF values.
Chen (2019)	Taiwan	To assess the effect of a single music therapy intervention on multiple mood categories and HRV for women actively being treated for breast cancer.	Randomized control trial	100 patients undergoing cancer treatment	5-minute recording, no positioning information given; ECG device; frequency domain as primary	Women who completed single session music intervention reduced symptoms post intervention compared to control group. Higher LF/HF ratio reported at baseline, but no post intervention data was given.
Aoki (2023)	Japan	To assess if HRV would be useful in evaluating fatigue and quality of life of women with breast cancer undergoing radiotherapy.	Cohort study	75 patients undergoing cancer treatment	2-minute recording, sitting; PPG device; frequency domain as primary	Cognitive and physical fatigue were highest at baseline and decreased by midpoint of treatment. Similarly, a decrease in LF/HF ratio was seen by midpoint of treatment.

Masel (2016)	Austria	To assess if HRV a valid representation for subjective pain for patients in palliative care with cancer break through pain.	Pilot study	10 patients undergoing cancer treatment	24-hour recording, no positioning data given; ECG device; frequency domain as primary	Pain reduction was seen post opioid administration. Log LF/HF ratio decreased in patients with >2 point reduction on the NRS.
Lee (2022)	Taiwan	To assess if there is a difference in HRV measures and quality of life measures when given either Qigong, mindfulness intervention or no intervention in cancer survivors at least 1 month out of treatment.	Quasi-experimental	125 cancer survivors	5-minute recording, sitting; PPG device; time domain as primary	Both Qigong and mindfulness interventions had short-term effects in improving overall physical and mental health, and quality of life. Increase in SDNN and total power were noted in the short term, but decreased LF was reported in the long term.
Uchida (2017)	Japan	To assess if HRV is predictive of PACU emergent pain within a 12h hour window in post operative breast cancer surgery patients.	Retrospective study	20 patients undergoing cancer treatment	No positioning or recording time information given; PPG device; frequency domain as primary	There was no significant difference in pain intensity between the two groups immediately after admission to PACU. Patients in the intervention group required no analgesic agents for at least 12 hours after surgery. Increased HF and decreased LF/HF ratio values were associated with adequate pain intervention.

Fagundes (2011)	USA	To assess if fatigue level is related to HRV or epinephrine at baseline and during/after a social stressor in breast cancer survivors.	Cohort study	109 cancer survivors	Continuous recording, sitting; PPG device; time domain as primary	Higher fatigue was associated with decreased RMSSD values pre and post stressor.
Niederer (2013)	Germany	To assess if exercise over a 16-week period improves HRV measures and cancer related fatigue in both cancer survivors and patients undergoing cancer treatment.	Quasi-experimental	45 cancer survivors and those undergoing treatment	5-minute recordings, supine; PPG device; frequency domain as primary	Exercise programming improves quality of life and increases total power values. An increase in HF and decrease in LF was also observed post intervention.
Yesil (2018)	Turkey	To assess whether neuropathic pain is associated with changes in cardiac sympathovagal activity in patients with breast cancer.	Cohort study	70 patients undergoing cancer treatment	24-hour recording, no positioning information given; ECG device; time domain as primary	SDNN was lower and LF/HF ratio was higher in patients with neuropathic pain than in those without.
Fournié (2021)	France	To evaluate the feasibility of a 12-week program combining heart rate variability biofeedback and physical exercise in hematologic patients.	Cohort study	20 patients undergoing cancer treatment	5-minute recording, seated with knees at 90°, feet flat on the floor, hands on thighs, palms facing upward, and eyes closed; PPG device; time domain as primary	No changes in fatigue outcome measures noted despite a trend towards decreasing general/physical fatigue. SDNN and RMSSD did not change over time, but increased LF and HRV coherence ratio were noted.



Murofushi (2023)	Japan	To assess if HRV can provide an objective measure for bone metastasis pain during a period of radiotherapy.	Pilot study	11 patients undergoing cancer treatment	24-hour recording, no positioning information given; PPG device; frequency domain as primary	For all samples, the NRS score showed no significant relationship with mean LF/HF ratio and HF. In patients with an NRS $\geq 4$ , the NRS score was significantly associated with LF/HF ratio but not HF.
Guimond (2018)	Canada	To assess if measures of emotional regulation are associated with measures of psychological symptoms in patients with breast cancer receiving radiotherapy.	Cross-sectional	81 patients undergoing cancer treatment	5-minute recording, no positioning information given; PPG device; time domain as primary	Low emotional regulation was marginally associated with increased depression and fatigue between timepoints. HF was not associated with symptom change.
Uchida (2017)	Japan	To assess if low dose Remifentanil effects post operative pain and HRV in breast cancer surgery patients.	Retrospective study	20 patients undergoing cancer treatment	No positioning or recording time information given; PPG device; frequency domain as primary	After Remifentanil administration, the value of the NRS decreased. There were no significant differences in HF and LF/HF ratio was found between groups.

Legend:

PPG= photoplethysmogram power

SDNN= standard deviation of the normal-to-normal interval

TP= total power

HF= high frequency

PTSD= post-traumatic stress syndrome    HRV= heart rate variability    ECG=electrocardiogram    LF/HF ratio= low frequency/high frequency ratio

RMSSD = square root of mean squared differences of successive normal-to-normal intervals    NRS= numeric rating scale    LF= low frequency

PACU= post anesthesia care unit

#	Query	Results
	<a href="#">Accessibility Information and Tips</a>	
	<a href="#">Print Search History</a>	
S1	DE "Heart Rate Variability"	3,053
S2	TI ( (((Cardia* or Heart or pulse) N1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or heart-beat* or ((Respirat* or Sinus*) N1 Arrhythmi*)) ) OR AB ( (((Cardia* or Heart or pulse) N1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or heart-beat* or ((Respirat* or Sinus*) N1 Arrhythmi*)) ) OR KW ( (((Cardia* or Heart or pulse) N1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or heart-beat* or ((Respirat* or Sinus*) N1 Arrhythmi*)) )	30,224
S3	(DE "Parasympathetic Nervous System") OR (DE "Autonomic Nervous System")	7,682
S4	TI ( activit* or function* or tone* ) OR AB ( activit* or function* or tone* ) OR KW ( activit* or function* or tone* )	1,165,623
S5	TI ( (((vegetative or visceral or parasympathetic or autonomic) N2 nervous) and (activit* or function* or tone*)) ) OR AB ( (((vegetative or visceral or parasympathetic or autonomic)	3,252
S6	DE "Vagus Nerve"	2,534
S7	TI ( (((Cranial or vagus or vagal or tenth or pneumogastric or x) N1 (nerve* or nervus or tone)) or vagatom* ) ) OR AB ( (((Cranial or vagus or vagal or tenth or pneumogastric or x) N1 (nerve* or nervus or tone)) or vagatom* ) ) OR KW ( (((Cranial or vagus or vagal or tenth or pneumogastric or x) N1 (nerve* or nervus or tone)) or vagatom* ) )	4,367
S8	DE "Electrocardiography" AND (TI (variab*) OR AB (variab*) OR KW (variab*))	1,001
S9	TI ( ((Electrocardiogra* or EKG# or ECG# or (Monitoring N0 Holter) or Vectercardiogra* or Vecter-cardiogra* or polarcardiogra* or polar-cardiogra*) and variab*) ) OR AB ( ((Electrocardiogra* or EKG# or ECG# or (Monitoring N0 Holter) or Vectercardiogra* or Vecter-cardiogra* or polarcardiogra* or polar-cardiogra*) and variab*) ) OR KW ( ((Electrocardiogra* or EKG# or ECG# or (Monitoring N0 Holter) or Vectercardiogra* or Vecter-cardiogra* or polarcardiogra* or polar-cardiogra*) and variab*) )	1,213
S10	TI ( (Cardiac N2 (control* or activit* or function* or tone* or electrophysiolog*)) ) OR AB ( (Cardiac N2 (control* or activit* or function* or tone* or electrophysiolog*)) ) OR KW ( (Cardiac N2 (control* or activit* or function* or tone* or electrophysiolog*)) )	3,064
S11	S3 AND S4	4,522
S12	S1 OR S2 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11	39,011
S13	((DE "Pain") OR (DE "Acute Pain") OR (DE "Pain Measurement" OR DE "Pain Thresholds"))	53,017
S14	TI ( ((Acute or radia*) N1 (Ache* or hurt* or aching or suffer*)) ) OR AB ( ((Acute or radia*) N1 (Ache* or hurt* or aching or suffer*)) ) OR KW ( ((Acute or radia*) N1 (Ache* or hurt* or aching or suffer*)) )	497
S15	TI pain* OR AB pain* OR KW pain*	128,339
S16	DE "Fatigue"	14,326
S17	TI ( (Fatigu* OR Lassitude) ) OR AB ( (Fatigu* OR Lassitude) ) OR KW ( (Fatigu* OR Lassitude) )	31,300
S18	TI ( ((small N0 (fibre* OR fiber*) N0 neuropath*) OR erythermalgia* OR erythromelalgia* ) ) OR AB ( ((small N0 (fibre* OR fiber*) N0 neuropath*) OR erythermalgia* OR erythromelalgia* ) ) OR KW ( ((small N0 (fibre* OR fiber*) N0 neuropath*) OR erythermalgia* OR erythromelalgia* ) )	310
S19	TI ( (sciatic N0 (pals* OR lesion OR neuralgia OR neuralgia-neuritide* OR neuropath* OR neuritis#s)) ) OR AB ( (sciatic N0 (pals* OR lesion OR neuralgia OR neuralgia-neuritide* OR neuropath* OR neuritis#s)) ) OR KW ( (sciatic N0 (pals* OR lesion OR neuralgia OR neuralgia-neuritide* OR neuropath* OR neuritis#s)) )	28
S20	S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19	162,721
S21	DE "Neoplasms" OR DE "Benign Neoplasms" OR DE "Breast Neoplasms" OR DE "Endocrine Neoplasms" OR DE "Leukemias" OR DE "Melanoma" OR DE "Metastasis" OR DE "Nervous System Neoplasms" OR DE "Terminal Cancer"	62,044
S22	( TI ( (cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leuk#emi* OR erythroleuk#em* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastas#s OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR Retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumo#r* OR oncol* ) ) OR AB ( (cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leuk#emi* OR erythroleuk#em* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastas#s OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR Retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumo#r* OR oncol* ) ) OR ( KW ( (cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leuk#emi* OR erythroleuk#em* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastas#s OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR Retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinaemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumo#r* OR oncol* ) ) )	103,594
S23	S21 OR S22	105,196
S24	S12 AND S20 AND S23	141
	Friday, November 10, 2023 5:17:46 PM	

medRxiv preprint doi: <https://doi.org/10.1101/2023.11.10.23281100>; this version posted November 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Thursday, November 09, 2023 4:36:34 PM

#	Query	Results
S26	S12 AND S21 AND S25	554
S25	S22 OR S23 OR S24	988,402
S24	MW ( (cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leuk#emi* OR erythroleuk#em* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastas#s OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR Retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumo#r* OR oncol* ) )	716,499
S23	TI ( (cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leuk#emi* OR erythroleuk#em* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastas#s OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR Retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumo#r* OR oncol* ) ) OR AB ( (cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leuk#emi* OR erythroleuk#em* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastas#s OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR Retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumo#r* OR oncol* ) )	820,511
S22	(MH "Neoplasms+")	662,997
S21	S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20	430,304
S20	TI ( (sciatic N0 (pals* OR lesion OR neuralgia OR neuralgia-neuritide* OR neuropath* OR neurit#s) ) ) OR AB ( (sciatic N0 (pals* OR lesion OR neuralgia OR neuralgia-neuritide* OR neuropath* OR neurit#s) ) ) OR MW ( (sciatic N0 (pals* OR lesion OR neuralgia OR neuralgia-neuritide* OR neuropath* OR neurit#s) ) )	99
S19	TI ( ((small N0 (fibre* OR fiber*) N0 neuropath*) OR erythralgia* OR erythromelalgia* ) ) OR AB ( ((small N0 (fibre* OR fiber*) N0 neuropath*) OR erythralgia* OR erythromelalgia* ) ) OR MW ( ((small N0 (fibre* OR fiber*) N0 neuropath*) OR erythralgia* OR erythromelalgia* ) )	600
S18	(MH "Small Fiber Neuropathy")	53
S17	TI ( (Fatigu* OR Lassitude ) ) OR AB ( (Fatigu* OR Lassitude ) ) OR MW ( (Fatigu* OR Lassitude ) )	57,553
S16	(MH "Fatigue")	21,993
S15	TI pain* OR AB pain* OR MW pain*	383,645
S14	TI ( ((Acute or radia*) N1 (Ache* or hurt* or aching or suffer*)) ) OR AB ( ((Acute or radia*) N1 (Ache* or hurt* or aching or suffer*)) ) OR MW ( ((Acute or radia*) N1 (Ache* or hurt* or aching or suffer*)) )	1,113
S13	(MH "Pain") OR (MH "Acute Pain (Saba CCC)") OR (MH "Acute Pain Control (Saba CCC)") OR (MH "Pain Measurement") OR (MH "Pain Threshold") OR (MH "Cancer Pain")	125,740
S12	S1 OR S2 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11	85,476
S11	TI ( (Cardiac N2 (control* or activit* or function* or tone* or electrophysiolog*)) ) OR AB ( (Cardiac N2 (control* or activit* or function* or tone* or electrophysiolog*)) ) OR MW ( (Cardiac N2 (control* or activit* or function* or tone* or electrophysiolog*)) )	16,088
S10	TI ( ((Electrocardiogra* or EKG# or ECG# or (Monitoring NO Holter) or Vectercardiogra* or Vecter-cardiogra* or polarcardiogra* or polar-cardiogra* and variab* ) ) OR AB ( ((Electrocardiogra* or EKG# or ECG# or (Monitoring NO Holter) or Vectercardiogra* or Vecter-cardiogra* or polarcardiogra* or polar-cardiogra* and variab* ) ) OR MW ( ((Electrocardiogra* or EKG# or ECG# or (Monitoring NO Holter) or Vectercardiogra* or Vecter-cardiogra* or polarcardiogra* or polar-cardiogra* and variab* ) )	4,151
S9	(MH "Electrocardiography") AND (TI (variab*) OR AB (variab*) OR MW (variab*))	3,610
S8	TI ( (((Cranial or vagus or vagal or tenth or pneumogastric or x) N1 (nerve* or nervus or tone)) or vagatom* ) ) OR AB ( (((Cranial or vagus or vagal or tenth or pneumogastric or x) N1 (nerve* or nervus or tone)) or vagatom* ) ) OR MW ( (((Cranial or vagus or vagal or tenth or pneumogastric or x) N1 (nerve* or nervus or tone)) or vagatom* ) )	6,791
S7	(MH "Vagus Nerve")	1,595
S6	TI ( (((vegetative or visceral or parasympathetic or autonomic) N2 nervous) and (activit* or function* or tone*)) ) OR AB ( (((vegetative or visceral or parasympathetic or autonomic) N2 nervous) and (activit* or function* or tone*)) ) OR MW ( (((vegetative or visceral or parasympathetic or autonomic) N2 nervous) and (activit* or function* or tone*)) )	2,442
S5	S3 AND S4	3,005
S4	TI ( activit* or function* or tone* ) OR AB ( activit* or function* or tone* ) OR MW ( activit* or function* or tone* )	992,617
S3	(MH "Parasympathetic Nervous System" OR MH "Autonomic Nervous System")	5,952
S2	TI ( (((Cardia* or Heart or pulse) N1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or heart-beat* or ((Respirat* or Sinus*) N1 Arrhythmi*)) ) OR AB ( (((Cardia* or Heart or pulse) N1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or heart-beat* or ((Respirat* or Sinus*) N1 Arrhythmi*)) ) OR MW ( (((Cardia* or Heart or pulse) N1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or heart-beat* or ((Respirat* or Sinus*) N1 Arrhythmi*)) )	62,695
S1	(MH "Heart Rate") AND (TI(variab*) OR AB(variab*) OR MW(variab*))	6,740

medRxiv preprint doi: <https://doi.org/10.1101/2025.01.08.25320191>; this version posted January 8, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

## Cochrane Search

Search Name: Hear Rate Variability- Cancer Patients-Draft 7

Date Run: 10/11/2023 11:31:02

Comment:

ID	Search	Hits
#1	MeSH descriptor: [Heart Rate] this term only	24584
#2	(variab*):ti,ab,kw	121731
#3	#1 AND #2	4455
#4	(((Cardia* or Heart or pulse) NEAR/1 (Atria* or Chronotro* or period or rate* or control*) or Heartbeat* or heart-beat* or ((Respirat* or Sinus*) NEAR/1 Arrhythmi*)):ti	4960
#5	MeSH descriptor: [Parasympathetic Nervous System] this term only	256
#6	MeSH descriptor: [Autonomic Nervous System] this term only	1497
#7	(activit* or function* or tone*):ti,ab,kw	483609
#8	(#5 OR #6) AND #7	1163
#9	(((vegetative or visceral or parasympathetic or autonomic) NEAR/2 nervous) and (activit* or function* or tone*)):ti,ab,kw	3058
#10	MeSH descriptor: [Vagus Nerve] this term only	486
#11	(((Cranial or vagus or vagal or tenth or pneumogastric or x) NEAR/1 (nerve* or nervus or tone)) or vagatom*):ti,ab,kw	2691
#12	MeSH descriptor: [Electrocardiography] this term only	8896
#13	#12 AND #2	1094
#14	(((Electrocardiogra* or EKG? or ECG? or (Monitoring NEAR/0 Holter) or Vectercardiogra* or Vecter-cardiogra* or polarcardiogra* or polar-cardiogra*) and variab*):ti	39
#15	((Cardiac NEAR/2 (control* or activit* or function* or tone* or electrophysiolog*)):ti,ab,kw	7981
#16	#3 OR #4 OR #8 OR #9 OR #10 OR #11 OR #13 OR #14 OR #15	20284

- #17 MeSH descriptor: [Pain] this term only 20160
- #18 MeSH descriptor: [Acute Pain] this term only 1192
- #19 MeSH descriptor: [Pain Measurement] this term only 24490
- #20 MeSH descriptor: [Pain Threshold] this term only 2141
- #21 MeSH descriptor: [Cancer Pain] this term only 471
- #22 (((Acute or radia\* NEAR/1 (Ache\* or hurt\* or aching or suffer\*))) :ti,ab,kw 240
- #23 (pain\*):ti,ab,kw 240777
- #24 MeSH descriptor: [Fatigue] this term only 8405
- #25 ((Fatigu\* or Lassitude)):ti,ab,kw 44423
- #26 MeSH descriptor: [Small Fiber Neuropathy] this term only 23
- #27 (((small NEAR/0 (fibre\* or fiber\*) NEAR/0 neuropath\*) or erythermalgia\* or erythromelalgia\*)):ti,ab,kw 28
- #28 MeSH descriptor: [Sciatic Neuropathy] this term only 9
- #29 ((sciatic NEAR/0 (pals\* or lesion or neuralgia or neuralgia-neuritide\* or neuropath\* or neurit?s))):ti,ab,kw 0
- #30 {OR #17-#29} 272529
- #31 MeSH descriptor: [Neoplasms] explode all trees 113268
- #32 ((cancer or cancers or cancerous or carcinoma\* or adenocarcinoma\* or hepatocarcinoma\* or carcinosarcoma\* or sarcoma\* or histiocytoma\* or fibrosarcoma\* or osteosarcoma\* or chondrosarcoma\* or lymphosarcoma\* or rhabdomyosarcoma\* or leuk?emi\* or erythroleuk?em\* or lymphoma\* or melanoma\* or hodgkin\* or "multiple myeloma" or mesothelioma\* or neoplas\* or malignan\* or metastas?s or metastatic or carcinoid\* or neuroblastoma\* or "Mycosis Fungoides" or "Sezary Syndrome" or Retinoblastoma\* or pheochromocytoma\* or nephroblastoma\* or choriocarcinoma\* or "Pleuropulmonary Blastoma" or "Pleuropulmonary Blastomas" or glioblastoma\* or glioma\* or astrocytoma\* or ependymoma\* or medulloblastoma\* or meningioma\* or craniopharyngioma\* or myelodysplastic or myeloproliferative or macroglobulinemi\* or macroglobulinaemi\* or pineoblastoma\* or thymoma\* or tumo?r\* or oncol\*)):ti,ab,kw 288103
- #33 {OR #31-#32} 293001

#34 #16 AND #30 AND #33 229

Query	Results
#21 #8 AND #17 AND #20	5154
#20 #18 OR #19	7599837
cancer:ti,ab,kw OR cancers:ti,ab,kw OR cancerous:ti,ab,kw OR carcinoma*:ti,ab,kw OR adenocarcinoma*:ti,ab,kw OR hepatocarcinoma*:ti,ab,kw OR carcinosarcoma*:ti,ab,kw OR sarcoma*:ti,ab,kw OR histiocytoma*:ti,ab,kw OR fibrosarcoma*:ti,ab,kw OR osteosarcoma*:ti,ab,kw OR chondrosarcoma*:ti,ab,kw OR lymphosarcoma*:ti,ab,kw OR rhabdomyosarcoma*:ti,ab,kw OR leuk\$emi*:ti,ab,kw OR erythroleuk\$em*:ti,ab,kw OR lymphoma*:ti,ab,kw OR melanoma*:ti,ab,kw OR hodgkin*:ti,ab,kw OR 'multiple myeloma':ti,ab,kw OR mesothelioma*:ti,ab,kw OR neoplas*:ti,ab,kw OR malignan*:ti,ab,kw OR metastasis:ti,ab,kw OR metastases:ti,ab,kw OR metastatic:ti,ab,kw OR carcinoid*:ti,ab,kw OR neuroblastoma*:ti,ab,kw OR 'mycosis fungoides':ti,ab,kw OR 'sezary syndrome':ti,ab,kw OR retinoblastoma*:ti,ab,kw OR pheochromocytoma*:ti,ab,kw OR nephroblastoma*:ti,ab,kw OR choriocarcinoma*:ti,ab,kw OR 'pleuropulmonary blastoma':ti,ab,kw OR 'pleuropulmonary blastomas':ti,ab,kw OR glioblastoma*:ti,ab,kw OR glioma*:ti,ab,kw OR astrocytoma*:ti,ab,kw OR ependymoma*:ti,ab,kw OR medulloblastoma*:ti,ab,kw OR meningioma*:ti,ab,kw OR craniopharyngioma*:ti,ab,kw OR myelodysplastic:ti,ab,kw OR myeloproliferative:ti,ab,kw OR macroglobulinemi*:ti,ab,kw OR macroglobulinaemi*:ti,ab,kw OR pineoblastoma*:ti,ab,kw OR thymoma*:ti,ab,kw OR tumo\$r*:ti,ab,kw OR oncol*:ti,ab,kw	6514366
#19	6514366
#18 'neoplasm'/exp	6290897
#17 #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16	1736879
(sciatic NEAR/1 (pals* OR lesion OR neuralgia OR 'neuralgia neuritide*' OR neuropath* OR neurit\$)):ti,ab,kw	667
#16 ((small NEAR/1 (fibre* OR fiber*) NEAR/1 neuropath*):ti,ab,kw) OR erythromelalgia*:ti,ab,kw OR erythromelalgia*:ti,ab,kw	3549
#15	3549
#14 'small fiber neuropathy'/de OR 'sciatic neuropathy'/de	2841
#13 fatigu*:ti,ab,kw OR lassitude:ti,ab,kw	216159
#12 'fatigue'/de	281217
#11 pain*:ti,ab,kw	1343325
#10 ((acute OR radia*) NEAR/2 (ache* OR hurt* OR aching OR suffer*)):ti,ab,kw	11296
#9 'pain'/de OR 'pain measurement'/de OR 'pain threshold'/de OR 'cancer pain'/de	445850
#8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7	521833
#7 (cardiac NEAR/3 (control* OR activit* OR function* OR tone* OR electrophysiolog*)):ti,ab,kw ('electrocardiography'/de OR 'electrocardiogram'/de) AND variab*:ti,ab,kw OR ((electrocardiogra*:ti,ab,kw OR ekg\$:ti,ab,kw OR ecg\$:ti,ab,kw OR ((monitoring NEAR/1 holter):ti,ab,kw) OR vectercardiogra*:ti,ab,kw OR 'vecter cardiogra*':ti,ab,kw OR polarcardiogra*:ti,ab,kw OR 'polar cardiogra*':ti,ab,kw) AND variab*:ti,ab,kw) (((cranial OR vagus OR vagal OR tenth OR pneumogastric OR x) NEAR/2 (nerve* OR nervus OR tone)):ti,ab,kw) OR vagatom*:ti,ab,kw	122428
#6	122428
#5 (((vegetative OR visceral OR parasympathetic OR autonomic) NEAR/3 nervous):ti,ab,kw) AND (activit*:ti,ab,kw OR function*:ti,ab,kw OR tone*:ti,ab,kw)	35182
#4 ('autonomic nervous system'/de OR 'parasympathetic nervous system physiology'/de) AND (activit*:ti,ab,kw OR function*:ti,ab,kw OR tone*:ti,ab,kw)	57184
#3 (((cardia* OR heart OR pulse) NEAR/2 (atria* OR chronotro* OR period OR rate* OR control*)):ti,ab,kw) OR heartbeat*:ti,ab,kw OR 'heart beat*':ti,ab,kw OR (((respirat* OR sinus*) NEAR/2 arrhythmi*):ti,ab,kw)	23470
#2	23470
#1 ('heart rate'/exp OR 'heart rate') AND variab*:ti,ab,kw	28746
	325390
	70329



medRxiv preprint doi: <https://doi.org/10.1101/2025.01.08.25320191>; this version posted January 8, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

10-Nov-23  
10-Nov-23

10-Nov-23  
10-Nov-23  
10-Nov-23

10-Nov-23

10-Nov-23  
10-Nov-23  
10-Nov-23  
10-Nov-23  
10-Nov-23  
10-Nov-23  
10-Nov-23  
10-Nov-23  
10-Nov-23  
10-Nov-23

10-Nov-23

10-Nov-23

10-Nov-23

10-Nov-23

10-Nov-23  
10-Nov-23

## Scopus Search

1,752 results

( TITLE-ABS(((vegetative OR visceral OR parasympathetic OR autonomic) W/2 nervous) AND (activit\* OR function\* OR tone\*))) OR TITLE-ABS(((cardia\* OR heart OR pulse) W/1 (atria\* OR chronotro\* OR period OR rate\* OR control\*)) OR heartbeat\* OR heart-beat\* OR ((respirat\* OR sinus\*) W/1 arrhythmi\*)) OR TITLE-ABS(((cranial OR vagus OR vagal OR tenth OR pneumogastric OR x) W/1 (nerv\* OR nervus OR tone)) OR vagatom\*) OR TITLE-ABS(((electrocardiogra\* OR ekg OR ecg OR ekgs OR ecgs OR (monitoring W/0 holter) OR vectercardiogra\* OR vectercardiogra\* OR polarcardiogra\* OR polar-cardiogra\*) AND variab\*))

AND

TITLE-ABS

((acute OR radia\*) W/1 (ache\* OR hurt\* OR aching OR suffer\*)) OR TITLE-ABS(pain\*) OR TITLE-ABS((fatigu\* OR lassitude)) OR TITLE-ABS(((small W/0 (fibre\* OR fiber\*) W/0 neuropath\*) OR erythermalgia\* OR erythromelalgia\*)) OR TITLE-ABS((sciatic W/0 (pals\* OR lesion OR neuralgia OR neuralgia-neuritide\* OR neuropath\* OR neuritis OR neurites)))

AND

TITLE-

ABS((cancer OR cancers OR cancerous OR carcinoma\* OR adenocarcinoma\* OR hepatocarcinoma\* OR carcinosarcoma\* OR sarcoma\* OR histiocytoma\* OR fibrosarcoma\* OR osteosarcoma\* OR chondrosarcoma\* OR lymphosarcoma\* OR rhabdomyosarcoma\* OR leukemia\* OR leukaemi\* OR erythroleukaem\* OR erythroleukem\* OR lymphoma\* OR melanoma\* OR hodgkin\* OR "multiple myeloma" OR mesothelioma\* OR neoplas\* OR malignan\* OR metastasis OR metastases OR metastatic OR carcinoid\* OR neuroblastoma\* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma\* OR pheochromocytoma\* OR neuroblastoma\* OR choriocarcinoma\* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma\* OR glioma\* OR astrocytoma\* OR ependymoma\* OR medulloblastoma\* OR meningioma\* OR craniopharyngioma\* OR myelodysplastic OR myeloproliferative OR macroglobulinemi\* OR macroglobulinaemi\* OR pineoblastoma\* OR thymoma\* OR tumor\* OR tumour\* OR oncol\*))

6,999 results

( TITLE-ABS-

KEY ((( (vegetative OR visceral OR parasympathetic OR autonomic ) W/2 nervo us ) AND ( activit\* OR function\* OR tone\* ))) OR TITLE-ABS-KEY ((( (cardia\* OR heart OR pulse ) W/1 ( atria\* OR chronotro\* OR period OR rate\* OR control\* )) OR heartbeat\* OR heart-beat\* OR (( respirat\* OR sinus\* ) W/1 arrhythmi\* ))) OR TITLE-ABS-KEY ((( (cranial OR vagus OR vagal OR tenth OR pneumogastric OR x ) W/1 ( nerve\* OR nervus OR tone )) OR vagatom\* )) OR TITLE-ABS-KEY ((( electrocardiogra\* OR ekg OR ecg OR ekgs OR ecgs OR ( monitoring W/0 holter ) OR vectercardiogra\* OR vecter-cardiogra\* OR polarcardiogra\* OR polar-cardiogra\* ) AND variab\* ))

AND


TITLE-ABS-

KEY (( acute OR radia\* ) W/1 ( ache\* OR hurt\* OR aching OR suffer\* )) OR TITLE-ABS-KEY ( pain\* ) OR TITLE-ABS-KEY ( ( fatigu\* OR lassitude ) ) OR TITLE-ABS-KEY ((( (small W/0 ( fibre\* OR fiber\* ) W/0 neuropath\* ) OR erythermalgia\* OR erythromelalgia\* )) OR TITLE-ABS-KEY (( sciatic W/0 ( pals\* OR lesion OR neuralgia OR neuralgia-neuritide\* OR neuropath\* OR neuritis OR neurites )))

AND

TITLE-ABS-

KEY (( cancer OR cancers OR cancerous OR carcinoma\* OR adenocarcinoma\* OR hepatocarcinoma\* OR carcinosarcoma\* OR sarcoma\* OR histiocytoma\* OR fibrosarcoma\* OR osteosarcoma\* OR chondrosarcoma\* OR lymphosarcoma\* OR rhabdomyosarcoma\* OR leukemia\* OR leukaemia\* OR erythroleukaemia\* OR erythroleukemia\* OR lymphoma\* OR melanoma\* OR hodgkin\* OR "multiple myeloma" OR mesothelioma\* OR neoplas\* OR malignan\* OR metastasis OR metastases OR metastatic OR carcinoid\* OR neuroblastoma\* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma\* OR pheochromocytoma\* OR nephroblastoma\* OR choriocarcinoma\* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma\* OR glioma\* OR astrocytoma\* OR ependymoma\* OR medulloblastoma\* OR meningioma\* OR craniopharyngioma\* OR myelodysplastic OR myeloproliferative OR macroglobulinemia\* OR macroglobulinaemia\* OR pineoblastoma\* OR thymoma\* OR tumor\* OR tumour\* OR oncol\* ))



medRxiv preprint doi: <https://doi.org/10.1101/2025.01.08.25320191>; this version posted January 8, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

---

# Search Strategy from ProQuest

November 10 2023 18:34

---

**SEARCH STRATEGY**

medRxiv preprint doi: <https://doi.org/10.1101/2025.01.08.25320191>; this version posted January 8, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Set No.	Searched for	Databases	Results
S1	noft((((Cardia* or Heart or pulse) NEAR/1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or heart-beat* or ((Respirat* or Sinus*) NEAR/1 Arrhythmi*)))	ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations & Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations & Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts	754569
S3	noft((((vegetative or visceral or parasympathetic or autonomic) NEAR/2 nervous) and (activit* or function* or tone*)) )	ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations & Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations & Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts	53855
S4	MAINSUBJECT.EXACT("Heart rate")	ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations & Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations & Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts	315187

S6	<p>medRxiv preprint doi: <a href="https://doi.org/10.1101/2023.01.08.23280491">https://doi.org/10.1101/2023.01.08.23280491</a>; this version posted January 9, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.</p> <p>noft(((Cranial or vagus or vagal or tenth or pneumogastric or x) NEAR/1 (nerve* or nervus or tone)) or vagatom* )</p>	<p>ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations &amp; Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations &amp; Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts</p>	88604
S7	<p>MAINSUBJECT.EXACT("Heart rate") AND noft(variab*)</p>	<p>ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations &amp; Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations &amp; Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts</p>	56797
S8	<p>noft(((Electrocardiogra* or EKG? or ECG? or (Monitoring NEAR/0 Holter) or Vectercardiogra* or Vectercardiogra* or polarcardiogra* or polar-cardiogra*) and variab*))</p>	<p>ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations &amp; Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations &amp; Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts</p>	39998
S9	<p>noft((Cardiac NEAR/2 (control* or activit* or function* or tone* or electrophysiolog*)))</p>	<p>ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National</p>	161785



Security Archive, Dissertations & Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations & Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts

S10	[S1] OR [S3] OR [S4] OR [S6] OR [S7] OR [S8] OR [S9]	<p>ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations &amp; Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations &amp; Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts</p> <p>These databases are searched for part of your query.</p>	996678
S12	MAINSUBJECT.EXACT("Pain") OR MAINSUBJECT.EXACT("Pain management")	<p>ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations &amp; Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations &amp; Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts</p>	860675
S13	noft(((Acute or radia*) NEAR/1 (Ache* or hurt* or aching or suffer*)) OR pain*)	<p>ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations &amp; Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare</p>	7823310

		<p>Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations &amp; Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts</p>	
S14	MAINSUBJECT.EXACT("Fatigue") OR noft((Fatigue* or Lassitude))	<p>ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations &amp; Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations &amp; Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts</p>	805916
S15	noft(((small NEAR/0 (fibre* or fiber*) NEAR/0 neuropath*) or erythermalgia* or erythromelalgia*)) OR noft((sciatic NEAR/0 (pals* or lesion or neuralgia or neuralgia-neuritide* or neuropath* or neurit?s)))	<p>ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations &amp; Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations &amp; Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts</p>	6879
S16	[S12] OR [S13] OR [S14] OR [S15]	<p>ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations &amp; Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations &amp; Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News,</p>	8558603



ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American,

S17	<p>MAINSUBJECT.EXACT("Cancer") OR noft((cancer or cancers or cancerous or carcinoma* or adenocarcinoma* or hepatocarcinoma* or carcinosarcoma* or sarcoma* or histiocytoma* or fibrosarcoma* or osteosarcoma* or chondrosarcoma* or lymphosarcoma* or rhabdomyosarcoma* or leuk?emi* or erythroleuk?em* or lymphoma* or melanoma* or hodgkin* or "multiple myeloma" or mesothelioma* or neoplas* or malignan* or metastas?s or metastatic or carcinoid* or neuroblastoma* or "Mycosis Fungoides" or "Sezary Syndrome" or Retinoblastoma* or pheochromocytoma* or nephroblastoma* or choriocarcinoma* or "Pleuropulmonary Blastoma" or "Pleuropulmonary Blastomas" or glioblastoma* or glioma* or astrocytoma* or ependymoma* or medulloblastoma* or meningioma* or craniopharyngioma* or myelodysplastic or myeloproliferative or macroglobulinemi* or macroglobulinaemi* or pineoblastoma* or thymoma* or tumo?r* or oncol*) )</p>	<p>ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts These databases are searched for part of your query.</p> <p>ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations &amp; Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations &amp; Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts</p>	14565453
S18	[S10] AND [S16] AND [S17]	ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries	6850

		<p>American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations &amp; Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations &amp; Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts</p> <p>These databases are searched for part of your query.</p>	
S19	([S10] AND [S16] AND [S17]) AND stype.exact("Dissertations & Theses")	<p>ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations &amp; Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations &amp; Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts</p> <p>These databases are searched for part of your query.</p>	91

---

medRxiv preprint doi: <https://doi.org/10.1101/2025.01.08.25320191>; this version posted January 8, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Database copyright © 2023 ProQuest LLC. All rights reserved.

[Terms and Conditions](#) [Contact ProQuest](#)

## Medline Search

Ovid MEDLINE(R) ALL <1946 to November 08, 2023>

1	exp Heart Rate/ and variab*.ti,ab,kf,kw. (((Cardia* or Heart or pulse) adj2 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or heart-beat* or ((Respirat* or Sinus*) adj2	31825
2	Arrhythmi*).ti,ab,kf,kw. (Parasympathetic Nervous System/ or Autonomic Nervous System/) and	224772
3	(activit* or function* or tone*).ti,ab,kf,kw. (((vegetative or visceral or parasympathetic or autonomic) adj3 nervous) and	16638
4	(activit* or function* or tone*).ti,ab,kf,kw.	14958
5	Vagus Nerve/ (((Cranial or vagus or vagal or tenth or pneumogastric or x) adj2 (nerve* or	23164
6	nervus or tone)) or vagatom*).ti,ab,kf,kw.	38737
	(Electrocardiography/ and variab*.ti,ab,kf,kw.) or ((Electrocardiogra* or EKG? or ECG? or (Monitoring adj1 Holter) or Vectercardiogra* or Vecter-cardiogra* 7 or polarcardiogra* or polar-cardiogra*) and variab*).ti,ab,kf,kw.	22731
8	(Cardiac adj3 (control* or activit* or function* or tone* or electrophysiolog*).ti,ab,kf,kw.	80144
9	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 Pain/ or Acute Pain/ or Pain Measurement/ or Pain Threshold/ or Cancer	360405
10	Pain/	233972
11	((Acute or radia*) adj2 (Ache* or hurt* or aching or suffer*).ti,ab,kf,kw.	6974
12	pain*.ti,ab,kf,kw.	871995
13	Fatigue/	35584
14	(Fatigu* or Lassitude).ti,ab,kf,kw.	130599
15	Small Fiber Neuropathy/ ((small adj1 (fibre* or fiber*) adj1 neuropath*) or erythermalgia* or	326
16	erythromelalgia*).ti,ab,kf,kw.	2122
17	Sciatic Neuropathy/	2261
	(sciatic adj1 (pals* or lesion or neuralgia or neuralgia-neuritide* or	
18	neuropath* or neurit?s)).ti,ab,kf,kw.	451
19	or/10-18	1044216
20	exp Neoplasms/	3895438

(cancer or cancers or cancerous or carcinoma\* or adenocarcinoma\* or hepatocarcinoma\* or carcinosarcoma\* or sarcoma\* or histiocytoma\* or fibrosarcoma\* or osteosarcoma\* or chondrosarcoma\* or lymphosarcoma\* or rhabdomyosarcoma\* or leuk?emi\* or erythroleuk?em\* or lymphoma\* or melanoma\* or hodgkin\* or "multiple myeloma" or mesothelioma\* or neoplas\* or malignan\* or metastas?s or metastatic or carcinoid\* or neuroblastoma\* or "Mycosis Fungoides" or "Sezary Syndrome" or Retinoblastoma\* or pheochromocytoma\* or nephroblastoma\* or choriocarcinoma\* or "Pleuropulmonary Blastoma" or "Pleuropulmonary Blastomas" or glioblastoma\* or glioma\* or astrocytoma\* or ependymoma\* or medulloblastoma\* or meningioma\* or craniopharyngioma\* or myelodysplastic or myeloproliferative or macroglobulinemi\* or macroglobulinaemi\* or pineoblastoma\* or thymoma\* or tumo?r\* or

21 oncol\*).ti,ab,kf,kw.

4649704

22 20 or 21

5325255

23 9 and 19 and 22

1802

Entitlement	Database	#	Search Query	Results	Date Run
- WOS.SCI:	Web of Sci	1	(((((vegetative OR visceral OR parasympathetic OR autonomic) NEAR/2 nervous) AND (activit* OR function* OR tone*))) OR (((cardia* OR heart OR pulse) NEAR/1 (atria* OR chronotro* OR period OR rate* OR control*)) OR heartbeat* OR heart-beat* OR ((respirat* OR sinus*) NEAR/1 arrhythmi*))) OR (((cranial OR vagus OR vagal OR tenth OR pneumogastric OR x) NEAR/1 (nerve* OR nervus OR tone)) OR vagatom*)) OR (((electrocardiogra* OR ekg OR ecg OR ekgs OR ecgs OR (monitoring NEAR/0 holter) OR vectercardiogra* OR vectar-cardiogra* OR polarcardiogra* OR polar-cardiogra*) AND variab*))) (Title)	69800	Fri Nov 10 2023 14:55:21 GMT-0500 (Eastern Standard Time)
- WOS.SCI:	Web of Sci	2	(((((vegetative OR visceral OR parasympathetic OR autonomic) NEAR/2 nervous) AND (activit* OR function* OR tone*))) OR (((cardia* OR heart OR pulse) NEAR/1 (atria* OR chronotro* OR period OR rate* OR control*)) OR heartbeat* OR heart-beat* OR ((respirat* OR sinus*) NEAR/1 arrhythmi*))) OR (((cranial OR vagus OR vagal OR tenth OR pneumogastric OR x) NEAR/1 (nerve* OR nervus OR tone)) OR vagatom*)) OR (((electrocardiogra* OR ekg OR ecg OR ekgs OR ecgs OR (monitoring NEAR/0 holter) OR vectercardiogra* OR vectar-cardiogra* OR polarcardiogra* OR polar-cardiogra*) AND variab*))) (Abstract)	229307	Fri Nov 10 2023 14:55:32 GMT-0500 (Eastern Standard Time)
- WOS.SCI:	Web of Sci	3	(((((vegetative OR visceral OR parasympathetic OR autonomic) NEAR/2 nervous) AND (activit* OR function* OR tone*))) OR (((cardia* OR heart OR pulse) NEAR/1 (atria* OR chronotro* OR period OR rate* OR control*)) OR heartbeat* OR heart-beat* OR ((respirat* OR sinus*) NEAR/1 arrhythmi*))) OR (((cranial OR vagus OR vagal OR tenth OR pneumogastric OR x) NEAR/1 (nerve* OR nervus OR tone)) OR vagatom*)) OR (((electrocardiogra* OR ekg OR ecg OR ekgs OR ecgs OR (monitoring NEAR/0 holter) OR vectercardiogra* OR vectar-cardiogra* OR polarcardiogra* OR polar-cardiogra*) AND variab*))) (Topic)	298864	Fri Nov 10 2023 14:55:39 GMT-0500 (Eastern Standard Time)
- WOS.SCI:	Web of Sci	4	#3 OR #2 OR #1	298864	Fri Nov 10 2023 14:56:11 GMT-0500 (Eastern Standard Time)
- WOS.SCI:	Web of Sci	7	((acute OR radia*) NEAR/1 (ache* OR hurt* OR aching OR suffer*)) OR (pain*) OR ((fatigu* OR lassitude)) OR (((small NEAR/0 (fibre* OR fiber*) NEAR/0 neuropath*) OR erythermalgia* OR erythromelalgia*)) OR ((sciatic NEAR/0 (pals* OR lesion OR neuralgia OR neuralgia-neuritide* OR neuropath* OR neuritis OR neurites))) (Title) OR ((acute OR radia*) NEAR/1 (ache* OR hurt* OR aching OR suffer*)) OR (pain*) OR ((fatigu* OR lassitude)) OR (((small NEAR/0 (fibre* OR fiber*) NEAR/0 neuropath*) OR erythermalgia* OR erythromelalgia*)) OR ((sciatic NEAR/0 (pals* OR lesion OR neuralgia OR neuralgia-neuritide* OR neuropath* OR neuritis OR neurites))) (Abstract)	1110163	Fri Nov 10 2023 14:56:56 GMT-0500 (Eastern Standard Time)
- WOS.SCI:	Web of Sci	8	((acute OR radia*) NEAR/1 (ache* OR hurt* OR aching OR suffer*)) OR (pain*) OR ((fatigu* OR lassitude)) OR (((small NEAR/0 (fibre* OR fiber*) NEAR/0 neuropath*) OR erythermalgia* OR erythromelalgia*)) OR ((sciatic NEAR/0 (pals* OR lesion OR neuralgia OR neuralgia-neuritide* OR neuropath* OR neuritis OR neurites))) (Topic)	1263178	Fri Nov 10 2023 14:57:10 GMT-0500 (Eastern Standard Time)
- WOS.SCI:	Web of Sci	9	#7 OR #8	1263178	Fri Nov 10 2023 14:57:37 GMT-0500 (Eastern Standard Time)
- WOS.SCI:	Web of Sci	10	adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leukemi* OR leukaemi* OR erythroleukaem* OR erythroleukem* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leukemi* OR leukaemi* OR erythroleukaem* OR erythroleukem* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Abstract)	5120755	Fri Nov 10 2023 14:58:50 GMT-0500 (Eastern Standard Time)
- WOS.SCI:	Web of Sci	11	((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leukemi* OR leukaemi* OR erythroleukaem* OR erythroleukem* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Topic)	5661623	Fri Nov 10 2023 14:58:57 GMT-0500 (Eastern Standard Time)
- WOS.SCI:	Web of Sci	12	#10 OR #11	5661623	Fri Nov 10 2023 14:59:09 GMT-0500 (Eastern Standard Time)
- WOS.SCI:	Web of Sci	13	#12 AND #9 AND #4	1551	Fri Nov 10 2023 14:59:27 GMT-0500 (Eastern Standard Time)

medRxiv preprint doi: <https://doi.org/10.1101/2023.11.08.23292009>; this version posted January 8, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Appendix 1. Mixed Methods Appraisal Tool Results

MIXED METHODS APPRAISAL TOOL Randomized Trials							
ITEM	S1	S2	1	2	3	4	5
Lee y, 2018	Yes	Yes	Can't tell	Yes	No	Can't tell	Yes
Burch J, 2020	Yes	Yes	Yes	Yes	No	Can't tell	No
Cheng 2019	Yes	Yes	Can't tell	Yes	Yes	Can't tell	Yes
Fernandez-Lao 2012	Yes	Yes	Yes	Yes	Can't tell	Yes	Yes
Chen S, 2019	Yes	Yes	Yes	Yes	Yes	Can't tell	Yes

MIXED METHODS APPRAISAL TOOL Non-Randomized Trials							
ITEM	S1	S2	1	2	3	4	5
Tsai H, 2021	Yes	Yes	Yes	Yes	Yes	No	Yes
Riesenberg H, 2009	Yes	Yes	Yes	Yes	Yes	Can't tell	Yes





Appendix 1. Mixed Methods Appraisal Tool Results

---

Uchida S, 2017	Yes	Yes	Yes	Yes	Yes	No	Yes
-------------------	-----	-----	-----	-----	-----	----	-----

---